SG11201504115XA - Novel inhibitor compounds of phosphodiesterase type 10a - Google Patents
Novel inhibitor compounds of phosphodiesterase type 10aInfo
- Publication number
- SG11201504115XA SG11201504115XA SG11201504115XA SG11201504115XA SG11201504115XA SG 11201504115X A SG11201504115X A SG 11201504115XA SG 11201504115X A SG11201504115X A SG 11201504115XA SG 11201504115X A SG11201504115X A SG 11201504115XA SG 11201504115X A SG11201504115X A SG 11201504115XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor compounds
- phosphodiesterase type
- novel inhibitor
- novel
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729877P | 2012-11-26 | 2012-11-26 | |
PCT/EP2013/074532 WO2014079995A2 (en) | 2012-11-26 | 2013-11-25 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201504115XA true SG11201504115XA (en) | 2015-07-30 |
Family
ID=49681010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201504115XA SG11201504115XA (en) | 2012-11-26 | 2013-11-25 | Novel inhibitor compounds of phosphodiesterase type 10a |
Country Status (16)
Country | Link |
---|---|
US (2) | US9790203B2 (en) |
EP (1) | EP2922842B1 (en) |
JP (1) | JP2016500091A (en) |
KR (1) | KR20150088873A (en) |
CN (1) | CN104995183B (en) |
AU (1) | AU2013349671B2 (en) |
BR (1) | BR112015012156A2 (en) |
CA (1) | CA2891995A1 (en) |
ES (1) | ES2639956T3 (en) |
HK (1) | HK1211581A1 (en) |
IL (1) | IL238739A0 (en) |
MX (1) | MX2015006539A (en) |
RU (1) | RU2015125306A (en) |
SG (1) | SG11201504115XA (en) |
TW (1) | TW201422604A (en) |
WO (1) | WO2014079995A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11427595B2 (en) | 2018-10-22 | 2022-08-30 | Trustees Of Boston University | Compositions and methods for inhibiting viral infection |
GB202002926D0 (en) | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100386542B1 (en) * | 1993-12-29 | 2003-10-11 | 후지사와 야꾸힝 고교 가부시키가이샤 | Pyrazolopyridine Adenosine Antagonists |
DK1104758T3 (en) * | 1999-12-03 | 2003-10-20 | Pfizer Prod Inc | Acetylene derivatives as anti-inflammatory / analgesic drugs |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US20030166476A1 (en) | 2002-01-31 | 2003-09-04 | Winemiller Mark D. | Lubricating oil compositions with improved friction properties |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
MXPA06014236A (en) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions. |
WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
EP1841757B1 (en) | 2005-01-07 | 2010-06-30 | Pfizer Products Incorporated | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
US20090023756A1 (en) | 2006-02-23 | 2009-01-22 | Pfizer Inc | Substituted quinazolines as pde10 inhibitors |
US20070287707A1 (en) | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
CA2644850A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
PT2057153E (en) | 2006-07-10 | 2012-11-14 | Lundbeck & Co As H | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
CA2706866A1 (en) | 2007-11-30 | 2009-06-04 | Biotie Therapies Gmbh | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
JP2010070514A (en) * | 2008-09-19 | 2010-04-02 | Toray Ind Inc | Pyrazole derivative and its pharmaceutical application |
US20100120763A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
US8852554B2 (en) | 2009-10-30 | 2014-10-07 | Janssen Pharmaceutica Nv | Radiolabelled PDE10 ligands |
TWI485151B (en) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | Heteroaromatic phenylimidazole derivatives as pde 10a enzyme inhibitors |
KR101199229B1 (en) * | 2010-06-18 | 2012-11-08 | 주식회사 알파켐 | Fluoranthene derivatives and organic electroluminescent device using the same |
PL2637704T3 (en) | 2010-11-10 | 2015-08-31 | H Lundbeck As | Radiolabelled phenylimidazole-based ligands |
US8691821B2 (en) | 2010-11-11 | 2014-04-08 | Bristol-Myers Squibb Company | Oxazolidinones as modulators of mGluR5 |
US20120214842A1 (en) | 2011-02-18 | 2012-08-23 | Exonhit Therapeutics Sa | Methods for treating diseases of the retina |
CN103159738B (en) * | 2011-12-19 | 2016-09-07 | 上海泓博智源医药股份有限公司 | The heteroaryl aroma compounds of alkynyl bridging and application thereof |
-
2013
- 2013-11-22 US US14/087,680 patent/US9790203B2/en active Active
- 2013-11-25 SG SG11201504115XA patent/SG11201504115XA/en unknown
- 2013-11-25 KR KR1020157017059A patent/KR20150088873A/en not_active Application Discontinuation
- 2013-11-25 WO PCT/EP2013/074532 patent/WO2014079995A2/en active Application Filing
- 2013-11-25 ES ES13798625.3T patent/ES2639956T3/en active Active
- 2013-11-25 EP EP13798625.3A patent/EP2922842B1/en active Active
- 2013-11-25 CN CN201380061194.XA patent/CN104995183B/en not_active Expired - Fee Related
- 2013-11-25 RU RU2015125306A patent/RU2015125306A/en not_active Application Discontinuation
- 2013-11-25 JP JP2015543443A patent/JP2016500091A/en active Pending
- 2013-11-25 AU AU2013349671A patent/AU2013349671B2/en not_active Expired - Fee Related
- 2013-11-25 CA CA2891995A patent/CA2891995A1/en not_active Abandoned
- 2013-11-25 MX MX2015006539A patent/MX2015006539A/en unknown
- 2013-11-25 BR BR112015012156A patent/BR112015012156A2/en not_active IP Right Cessation
- 2013-11-26 TW TW102143091A patent/TW201422604A/en unknown
-
2015
- 2015-05-10 IL IL238739A patent/IL238739A0/en unknown
- 2015-12-16 HK HK15112371.7A patent/HK1211581A1/en unknown
-
2017
- 2017-10-04 US US15/724,410 patent/US20180030033A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2922842B1 (en) | 2017-06-14 |
WO2014079995A2 (en) | 2014-05-30 |
US9790203B2 (en) | 2017-10-17 |
AU2013349671B2 (en) | 2018-03-29 |
AU2013349671A1 (en) | 2015-05-21 |
ES2639956T3 (en) | 2017-10-30 |
CA2891995A1 (en) | 2014-05-30 |
TW201422604A (en) | 2014-06-16 |
KR20150088873A (en) | 2015-08-03 |
IL238739A0 (en) | 2015-06-30 |
HK1211581A1 (en) | 2016-05-27 |
WO2014079995A3 (en) | 2014-07-17 |
US20180030033A1 (en) | 2018-02-01 |
EP2922842A2 (en) | 2015-09-30 |
RU2015125306A (en) | 2017-01-10 |
JP2016500091A (en) | 2016-01-07 |
US20140148461A1 (en) | 2014-05-29 |
CN104995183A (en) | 2015-10-21 |
BR112015012156A2 (en) | 2017-07-11 |
CN104995183B (en) | 2018-04-06 |
MX2015006539A (en) | 2015-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263262B (en) | Compounds useful as inhibitors of atr kinase | |
SG10201605196PA (en) | Novel Inhibitor Compounds Of Phosphodiesterase Type 10A | |
HK1215253A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
HK1201519A1 (en) | Inhibitors of phosphodiesterase type 10a 10a | |
HK1211921A1 (en) | Inhibitor compounds | |
HK1211942A1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
HK1210178A1 (en) | Substituted pyridopyrazines as syk inhibitors syk | |
HK1219273A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
HK1211024A1 (en) | Inhibitors of syk syk | |
HK1206728A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
PL2888228T3 (en) | Inhibitors of cd40-traf6 interaction | |
HK1211581A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
GB201211019D0 (en) | Inhibitor compounds | |
PT2784068E (en) | Phosphodiesterase 4 inhibitor capable of avoiding vomiting | |
HK1211284A1 (en) | Inhibitor compounds of phosphodiesterase type 10a 10a |